NICE says yes to AstraZeneca's Iressa for NSCLC and Roche's Xeloda for gastric cancer.
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, says that it is now poised to recommend AstraZeneca's Iressa (gefitinib) for some NHS non-small cell lung cancer (NSCLC) patients after initially saying that it wanted more information. The firm has also managed to convince the institute that its patient access scheme would be of benefit.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.